Matters of the HAART: An Update on Current Treatment Options for HIV

Size: px
Start display at page:

Download "Matters of the HAART: An Update on Current Treatment Options for HIV"

Transcription

1 Matters of the HAART: An Update on Current Treatment Options for HIV Jason Alegro, PharmD, BCPS Assistant Professor of Clinical Sciences, Roosevelt University Infectious Diseases Clinical Pharmacy Specialist, Mount Sinai Hospital

2 Disclosures Dr. Alegro declares no conflicts of interest, real or apparent, and no financial interests in any company, product, or service mentioned in this program, including grants, employment, gifts, stock holdings and honoraria.

3 Pharmacist Learning Objectives 1. Describe the pathophysiology of HIV disease and the role of different highly active antiretroviral therapy (HAART) classes in inhibiting the retroviral replication process. 2. Discuss the mechanism of action, adverse effects, drug interactions, and other clinical considerations of HIV treatment options commonly used in practice. 3. Discuss current treatment guidelines, including new updates for HIV treatment and pre-exposure prophylaxis in selected patients.

4 Pharmacy Technician Learning Objectives 1. Describe the role of antiretroviral therapy in treating HIV/AIDS. 2. Recognize common adverse effects of antiretroviral agents. 3. List examples of patients who would be indicated for pre-exposure prophylaxis with antiretrovirals.

5 Pre-Assessment Questions 1. Which of the following is TRUE regarding tenofovir alafenamide (TAF)? A. It is more nephrotoxic compared to TDF B. It has less bone mineral density loss compared to TDF C. It has a higher rate of treatment failure compared to TDF D. It should not be considered as a component of first-line combination ART regimens

6 Pre-Assessment Questions 2. Which of the following is an appropriate first-line treatment option for HIV? A. Dolutegravir + efavirenz + cobicistat B. Emtricitabine + tenofovir alafenamide + elvitegravir + cobicistat C. Darunavir/r + raltegravir + abacavir D. Lamivudine + rilpivirine + atazanavir/r

7 Pre-Assessment Questions 3. Which of the following patients would be an appropriate candidate for PrEP? A. 35 y.o. HIV-negative heterosexual male with an HIV infected partner B. 22 y.o. intranasal cocaine and heroin user C. 47 y.o. HIV-positive homosexual male with an HIV-negative partner D. 29 y.o. HIV-negative homosexual male with a mutually monogamous relationship with an HIV negative partner

8 Human Immunodeficiency Virus

9 Human Immunodeficiency Virus Definitions: Human Immunodeficiency Virus (HIV) See etiology section Acquired Immunodeficiency Syndrome (AIDS) Advanced stage of HIV infection Defined as a CD4 count <200 cells/mm 3, CD4% of < 14%, or presence of an AIDS-defining illness

10 AIDS-defining illnesses Candidiasis of bronchi, trachea, esophagus, or lungs Coccidioidomycosis Cryptococcosis Cryptosporidiosis, chronic intestinal (greater than 1 month's duration) Cytomegalovirus disease (particularly CMV retinitis) Encephalopathy, HIV-related Histoplasmosis Kaposi's sarcoma Lymphoma, multiple forms Mycobacterium avium complex Tuberculosis Pneumocystis jirovecii pneumonia Toxoplasmosis of brain Wasting syndrome due to HIV Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morbidity and Mortality Weekly Report, December 18, 1992/41 (RR-17), 1993

11 HIV Disease RNA retrovirus that attacks CD4+ T-helper cells of the immune system HIV drugs are antiretrovirals (ARV s) and can be seen as antiretroviral therapy (ART), combined antiretroviral therapy (cart) or highly-active antiretroviral therapy (HAART) HIV viral load: indicates response to ART goal is to have an undetectable viral load 11

12 Epidemiology - Transmission Requires transmission from blood, semen, rectal fluids, vaginal fluids, or breast milk to a mucous membrane/damaged tissue OR via direct bloodstream inoculation Three primary modes Sexual (most common) Parenteral Perinatal

13 Sexual Transmission of HIV Highest risk in receptive anorectal intercourse (1.4 transmissions per 100 sexual acts) Lower risk in vaginal receptive intercourse and both vaginal and anorectal insertive intercourse Condom use reduces risk of transmission ~80% Concurrent STI increases risk for contracting HIV HIV-infected partner s viral load affects transmission rates

14 Parenteral Transmission of HIV Needlesticks, IV drug use (sharing needles), receipt of blood products, organ transplants Transmission from sharing needles = 0.67 per 100 episodes Prior to 1985 before HIV antibody testing was available for blood products, recipients of HIV infected blood acquired the virus at a rate of >90% Needlestick from an HIV infected patient = 0.3 per 100 episodes Mucocutaneous exposure (blood splashes eyes, mouth, nose) = 0.09 per 100 exposures

15 Perinatal Transmission of HIV Most common mode of pediatric HIV transmission Mother-to-child transmission is 25% if no ART Viral suppression with ART can reduce this to <2% Breast feeding 5-10% in the first six months 15-20% through ~24 months

16 Etiology HIV is an enveloped single-stranded RNA retrovirus HIV-1 (most common in the U.S. and for global epidemic) and HIV-2 (found mostly in Western Africa) Evidence suggests that HIV arose from a zoonosis from primates infected with simian immunodeficiency virus (SIV) Transmission likely occurred through bush meat and keeping animals as pets (chimpanzees and sooty mangabeys)

17 The Virus 17

18 The HIV Life Cycle 1. Binding/Attachment ( - ) 2. Fusion ( - ) 3. Reverse Transcription ( - ) 4. Integration (-) 5. Replication 6. Assembly 7. Budding ( - )

19 19

20 The HIV Life Cycle 20

21 The HIV Life Cycle 21

22 The HIV Life Cycle 22

23 Antiretroviral Therapy

24 Goals of Antiretroviral Therapy Maximum and sustainable suppression of plasma HIV RNA Restoration and preservation of immune function Reduction in morbidity and mortality of HIV disease Improve duration and quality of life Prevention of HIV transmission

25 Principal Tenets of Antiretroviral Therapy Treatment for HIV requires combination ART Not curative, but can transform HIV disease into a chronic condition What happens if we didn t have ART or patients are non-adherent with their antiretrovirals?? ART is recommended in ALL HIV-infected individuals, regardless of CD4+ count 1,2 1. N Engl J Med Aug 27;373(9): N Engl J Med 2015; 373:

26 Antiretroviral classes Nuceloside/tide Reverse Transcriptase Inhibitors (NRTI s) Non-Nuceloside Reverse Transcriptase Inhibitors (NNRTI s) Protease Inhibitors (PI s) INtegrase Strand Transfer Inhibitors (INSTI s) Fusion Inhibitors Entry Inhibitors Combination Agents

27 NRTI s Agents: Abacavir (ABC, Ziagen) Lamivudine (3TC, Epivir) Emtricitabine (FTC, Emtriva) Tenofovir disoproxil fumarate (TDF, Viread) Tenofovir alafenamide (TAF, Vemlidy) Zidovudine (ZDV, AZT, Retrovir)

28 NRTI s Mechanism of Action: Structural similarity to natural nucleosides/nucleotides necessary to synthesize viral DNA Competitively binds to the enzyme reverse transcriptase, blocking HIV viral RNA-dependent DNA polymerase Results in DNA chain termination and stops further viral DNA synthesis Reverse Transcription Transcription Translation RNA DNA RNA Proteins

29 NRTI s Mechanism of Action: Structural similarity to natural nucleosides/nucleotides necessary to synthesize viral DNA Competitively binds to the enzyme reverse transcriptase, blocking HIV viral RNA-dependent DNA polymerase Results in DNA chain termination and stops further viral DNA synthesis Reverse Transcription Transcription Translation RNA DNA RNA Proteins

30 NRTI s Adverse Effects Class N/V/D, rash, headache, insomnia Boxed warning for lactic acidosis and hepatomegaly with steatosis (more with zidovudine, stavudine, didanosine) Abacavir Hypersensitivity reactions (can lead to death) Occurs within first six weeks of therapy, median onset 11 days Possible increased risk of myocardial infarction Tenofovir Renal toxicity, including ARF and/or Fanconi syndrome Osteomalacia and decreased bone mineral density TAF presumably has less renal and bone toxicity compared to TDF Emtricitabine Hyperpigementation of the palms/soles Lamivudine Headache, GI upset, diarrhea Hepatitis flare if active HBV infection Zidovudine Hematologic toxicities (macrocytic anemia and neutropenia) Myopathy

31 TDF vs. TAF Wohl, DA. (2015, February). CROI 2015 Metabolic Report: Vital Organs and HIV. Presented at the 22nd Conference on Retroviruses and Opportunistic Infections, Seattle, WA.

32 NRTI s Clinical Pearls All first-line treatment regimens contain TWO NRTI s (backbone) Co-formulations of FTC/TDF (Truvada), FTC/TAF (Descovy), and ABC/3TC (Epzicom) are serve as the backbone for most preferred regimens All require renal dose adjustments except abacavir Specific Agents Abacavir: Must screen for HLA-B*5701 allele prior to starting; If positive, use is contraindicated due to increased risk of serious, possibly fatal hypersensitivity reaction. Lamivudine and TDF have activity against Hepatitis B Zidovudine is the only available intravenous antiretroviral Recommended for peripartum administration if viral load >1000 Didanosine and stavudine uncommonly seen in modern practice due to ADE s

33 Agents: Efavirenz (EFV, Sustiva) Rilpivirine (RPV, Edurant) Nevirapine (NVP, Viramune) Etravirine (ETR, Intelence) NNRTI s

34 NNRTI s Mechanism of Action: Non-competitive inhibition of HIV reverse transcriptase Blocks HIV viral RNA-dependent DNA polymerase and results in chain termination ADEs: Class: rash, transaminitis (can be life threatening with nevirapine) Efavirenz Rilpivirine Nevirapine Etravirine CNS effects vivid dreams, nightmares, nocturnal dizziness, morning confusion, depersonalization fat redistribution, peripheral fat wasting, does-dependent QTc prolongation higher incidence of rash and severe fulminant hepatitis; SJS/TENS generally well tolerated; rash, GI distress, LFT abnormalities

35 NNRTI s Clinical Pearls NNRTI s have a low genetic barrier to resistance (i.e. one mutation will confer resistance), therefore not preferred first-line Caution in patients with hepatic insufficiency Efavirenz previously a first-line option in a combination with TDF and FTC (Atripla), however this is no longer a first-line option Rilpivirine absorption decrease with gastric acid suppression, so contraindicated with PPI s

36 Agents: Darunavir (DRV, Prezista) Atazanavir (ATV, Reyataz) Ritonavir (RTV, Norvir) Fosampreanvir (FPV, Lexiva) Indinavir (IDV, Crixivan) Lopinavir/ritonavir (LPV/r, Kaletra) Nelfinavir (NFV, Viracept) Saquinavir (SQV, Invirase) Tipranavir (TPV, Aptivus) Protease Inhibitors

37 Protease Inhibitors Adverse Effects Class: GI distress, metabolic changes (increased lipids, insulin insensitivity, changes in fat distribution) Atazanavir: hyperbilirubinemia, jaundice/scleral icterus Darunavir: transaminitis, rash Ritonavir: GI intolerance

38 Protease Inhibitors Drug Interactions BIG drug interaction class most are CYP 3A4 inhibitors and substrates DOAC s, antiarrhythmics, azole antifungals, oral contraceptives, statins, benzodiazepines, etc. Clinical Pearls Higher genetic barrier to resistance MANY side effects; darunavir and atazanavir improve upon these side effects, however they are still a major concern in use

39 PK Boosters Drug Interactions! Ritonavir (RTV, Norvir) CYP 3A4 inhibitor Darunavir/r Lopinavir/r Atazanavir/r Cobicistat (COBI, Tybost) CYP 3A4 inhibitor somewhat more selective than ritonavir (less drug interactions) Darunavir/COBI (Prezcobix) Stribild//Genvoya

40 Integrase Strand Transfer Inhibitors (INSTI s) Agents: Raltegravir (RAL, Isentress) Elvitegravir (EVG, Vitetka) Co-formulated with cobicistat to boost plasma levels Dolutegravir (DTG, Tivicay) Mechanism of Action Bind to HIV integrase and inhibits strand transfer that incorporates proviral DNA into chromosomal DNA

41 INSTI s ADEs: As a class, overall well tolerated with good long-term safety data Specific agents Dolutegravir: insomnia, headache, rash Elvitegravir: diarrhea, nausea Raltegravir: rash, increased CPK Clinical Pearls Overall well-tolerated Part of all primary treatment regimens in addition to NRTI backbone HIGH barrier to genetic resistance with dolutegravir Raltegravir and dolutegravir have minimal CYP interactions due to metabolism by UGT1A1 Elvitegravir is a major CYP 3A4 substrate and is formulated with cobicistat to optimize drug exposure

42 CCR5 Antagonist Agent: Maraviroc (Selzentry) Mechanism of Action: HIV requires viral gp120 to bind to CD4 and a surface chemokine co-receptor located on CD4+ cells, either CCR5 or CXCR4 Maraviroc allosterically inhibits gp120-ccr5 binding that blocks HIV attachment Viral tropism assay (Trofile test) must be performed before starting maraviroc. The patient s HIV strain must express CCR5 only ( R5 tropic ) in order to use maraviroc

43 Maraviroc ADEs: Generally well tolerated Cough, fever, upper respiratory infection Orthostatic hypotension Clinical Pearls CYP 3A4 and pgp substrate, so always check for drug interactions Although a well-tolerated drug, role is in the management of treatment experienced patients Lack of long-term safety data BID dosing Non-viral target Failure to meet non-inferiority to efavirenz

44 Fusion Inhibitor Agent: Enfuvirtide (Fuzeon) available only as SC injection! Mechanism of Action: HIV binds to the CD4+ cell using viral protein gp120; gp41 is an HIV transmembrane protein which undergoes a conformational change in order to allow fusion of the viral and host (CD4+) cell membrane Enfuvirtide binds to gp41 subunit of the viral envelope and prevents the conformational change necessary for viral fusion and entry into CD4+ cells

45 Enfuvirtide ADEs: Local injection site reactions (pain, erythema, induration, nodular cysts) Eosinophilia Bacterial pneumonia Clinical Pearls: Difficult dosing regimen to maintain adherence (SC injection q12h) Option for treatment-experienced patients with resistant virus Expensive Time-consuming reconstitution process

46 Post-Assessment Questions 1. Which of the following is TRUE regarding tenofovir alafenamide (TAF)? A. It is more nephrotoxic compared to TDF B. It has less bone mineral density loss compared to TDF C. It has a higher rate of treatment failure compared to TDF D. It should not be considered as a component of first-line combination ART regimens

47 Post-Assessment Questions 1. Which of the following is TRUE regarding tenofovir alafenamide (TAF)? A. It is more nephrotoxic compared to TDF B. It has less bone mineral density loss compared to TDF C. It has a higher rate of treatment failure compared to TDF D. It should not be considered as a component of first-line combination ART regimens

48 HIV Treatment Guidelines

49 Most Recent Guideline Updates (2017) ART regimens now classified into: Recommended Initial Regimens for Most People with HIV; and Recommended Initial Regimens in Certain Clinical Situations More robust safety data regarding advantages of tenofovir alafenamide (TAF) containing regimens compared to tenofovir disoproxil fumarate (TDF) containing regimens

50 The NRTI backbone All first-line antiretroviral regimens consist of an NRTI backbone of one of the following combinations: Tenofovir disoproxil fumarate + emtricitabine (Truvada) Tenofovir alafenamide + emtricitabine (Descovy) Abacavir + lamivudine (Epzicom) Emtricitabine (FTC) and lamivudine (3TC) are almost structurally identical, so these are not used together These backbones are effective, relatively safe, and relatively cheap drugs that have been well-studied to suppress viral load in combination with another core agent (INSTI s preferred)

51 First-line combination ART for treatmentnaïve HIV positive patients INSTI + NRTI combo dolutegravir + Epzicom 2 = Triumeq 1,2 dolutegravir + Truvada or Descovy elvitegravir/cobicistat/truvada = Stribild 1 elvitegravir/cobicistat/descovy = Genvoya 1 raltegravir + Truvada or Descovy PI + NRTI combo (now only first line for certain clinical situations) darunavir/r + Truvada or Descovy 1 Available as one tablet once daily 2 Must be negative for HLA-B*5701 allele 3 Active against Hepatitis B 4 Dose adjustment required if CrCl <50 51

52 Building blocks of combination first-line ART regimens based on class NRTI (nucleoside reverse transcriptase inhibitor) combos: abacavir 1 (Ziagen) + lamivudine 2, 3 (Epivir) = Epzicom Emtricitabine 2, 3 (Emtriva) + tenofovir disoproxil fumarate 2,3 (Viread, TDF) = Truvada Emtricitabine 2, 3 + tenofovir alafenamide 2 (Vemlidy, TAF) = Descovy INSTI s (Integrase-strand transfer inhibitors): raltegravir (Isentress) elivitegravir (Vitekta) + cobicistat (Tybost) Cobicistat acts as a PK booster (3A4 inhibitor) dolutegravir (Tivicay) PI (Protease Inhibitor) Darunavir (Prezista) + ritonavir (Norvir) Ritonavir acts as a PK booster (3A4 inhibitor) Darunavir/r = darunavir boosted by ritonavir 1 Must be negative for HLA-B*5701 allele 2 Active against Hepatitis B 3 Dose adjustment required if CrCl <50

53 First-line combination ART for treatmentnaïve HIV positive patients INSTI + NRTI combo dolutegravir + Epzicom 2 = Triumeq 1,2,3 dolutegravir + Truvada 4 or Descovy 4 elvitegravir/cobicistat/truvada = Stribild 3* (If CrCl <70 ml/min, should not initiate) elvitegravir/cobicistat/descovy = Genvoya 1, 4 raltegravir + Truvada 4 or Descovy 4 PI + NRTI combo (now only first line for certain clinical situations) darunavir/r + Truvada 4 or Descovy 4 1 Available as one tablet once daily 2 Must be negative for HLA-B*5701 allele 3 Not recommended if CrCl <50 4 Not recommended if CrCl <30

54 Juluca (dolutegravir/rilpivirine) NEW two-drug combination agent (INSTI + NNRTI) approved Nov FDA approval as the first two-drug complete regimen for treatment of HIV-1 infection in adults to replace current ART regimen in patients who meet the following: Virologically suppressed on their antiretroviral regimen for at least six months Have no history of antiretroviral treatment failure Have no resistance to active components of Juluca

55 Post-Assessment Questions 2. Which of the following is an appropriate first-line treatment option for HIV? A. Dolutegravir + efavirenz + cobicistat B. Emtricitabine + tenofovir alafenamide + elvitegravir + cobicistat C. Darunavir/r + raltegravir + abacavir D. Lamivudine + rilpivirine + atazanavir/r

56 Post-Assessment Questions 2. Which of the following is an appropriate first-line treatment option for HIV? A. Dolutegravir + efavirenz + cobicistat B. Emtricitabine + tenofovir alafenamide + elvitegravir + cobicistat C. Darunavir/r + raltegravir + abacavir D. Lamivudine + rilpivirine + atazanavir/r

57 Pre-Exposure Prophylaxis in HIV

58 Pre-Exposure Prophylaxis (PrEP) Administered to persons who are HIV negative, but are at high risk of being infected by HIV Reduces sexually transmitted HIV risk by 90% and IVDU risk by 70% if adherent Indications* Sexually active MSM at risk for HIV acquisition (IA) Heterosexually active men and women at risk for HIV acquisition (IA) Adult IV drug users at risk for HIV acquisition (IA) HIV discordant couples *At risk: Ongoing relationship with HIV positive partner Non monogamous relationship with HIV negative partner Gay or bisexual man who has had anal sex without a condom or been diagnosed with an STD in the past 6 months Heterosexual man or woman who does not regularly use condoms during sex with partners of unknown HIV status who are at substantial risk for infection Injection drug users who have shared injection equipment or been in drug treatment for IVDU in the past 6 months

59 Pre-Exposure Prophylaxis (PrEP) Prophylaxis is given with TDF/FTC (Truvada), one pill, once daily Patients on PrEP should follow up with their provider every three months for a repeat HIV test to ensure the patient has not seroconverted In PrEP clinical trials, none of the studies found significant concerns; some mild upset stomach or loss of appetite occurred within the first month of therapy Should test for Hepatitis B prior to initiating PrEP due to concerns for HBV flare if Truvada is discontinued

60 Post-Assessment Questions 3. Which of the following patients would be an appropriate candidate for PrEP? A. 35 y.o. HIV-negative heterosexual male with an HIV infected partner B. 22 y.o. intranasal cocaine and heroin user C. 47 y.o. HIV-positive homosexual male with an HIV-negative partner D. 29 y.o. HIV-negative homosexual male with a mutually monogamous relationship with an HIV negative partner

61 Post-Assessment Questions 3. Which of the following patients would be an appropriate candidate for PrEP? A. 35 y.o. HIV-negative heterosexual male with an HIV infected partner B. 22 y.o. intranasal cocaine and heroin user C. 47 y.o. HIV-positive homosexual male with an HIV-negative partner D. 29 y.o. HIV-negative homosexual male with a mutually monogamous relationship with an HIV negative partner

62 References 1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. Department of Health and Human Services. Available at Guidelines accessed January 20, Preexposure Prophylaxis for the Prevention of HIV Infection 2014: A Clinical Practice Guideline.

63 What questions can I answer for you?

64 Matters of the HAART: An Update on Current Treatment Options for HIV Jason Alegro, PharmD, BCPS Assistant Professor of Clinical Sciences, Roosevelt University Infectious Diseases Clinical Pharmacy Specialist, Mount Sinai Hospital

HIV Drugs and the HIV Lifecycle

HIV Drugs and the HIV Lifecycle HIV Drugs and the HIV Lifecycle Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject All HIV drugs work by interrupting different steps in HIV's

More information

HIV Management Update 2015

HIV Management Update 2015 9/30/15 HIV Management Update 2015 Larry Pineda, PharmD, PhC, BCPS Visiting Assistant Professor Pharmacy Practice and Administrative Science ljpineda@salud.unm.edu Pharmacist Learning Objectives Describe

More information

COMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL

COMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL Generic Name COMPREHENSIVE ANTIRETROVIRAL TABLE: NUCLOESIDE/TIDE REVERSE TRANSCRIPTASE INHIBITORS (N(t)RTIs) Abacavir ABC (Ziagen) Didanosine ddi (Videx EC) Emtricitabine FTC (Emtriva) Lamivudine 3TC (Epivir)

More information

HIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily

HIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily HIV MEDICATIONS AT A GLANCE Generic Name Trade Name Strength DIN Usual Dosage Single Tablet Regimen (STR) Products Efavirenz/ Emtricitabine/ rilpivirine/ elvitegravir/ cobicistat/ alafenamide Emtricitabine/

More information

Selecting an Initial Antiretroviral Therapy (ART) Regimen

Selecting an Initial Antiretroviral Therapy (ART) Regimen Selecting an Initial Antiretroviral Therapy (ART) Regimen An HIV Diagnosis is a Call to Action In support of the NYSDOH AIDS Institute s January 2018 call to action for patients newly diagnosed with HIV,

More information

Northwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care

Northwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care Northwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care www.nwaetc.org The Northwest AIDS Education and Training Center (NW AETC), located at the University

More information

THE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work

THE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work THE HIV LIFE CYCLE Understanding How Antiretroviral Medications Work DEFINITIONS Host: The animal or cell that another organism lives in. In HIV human CD4 T-cells are the host for HIV. Nucleus: The core

More information

Continuing Education for Pharmacy Technicians

Continuing Education for Pharmacy Technicians Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected

More information

An HIV Update Jan Clark, PharmD Specialty Practice Pharmacist

An HIV Update Jan Clark, PharmD Specialty Practice Pharmacist An HIV Update - 2019 Jan Clark, PharmD Specialty Practice Pharmacist 2 The goal of this program is to provide a review and update of HIV care and to provide a forum for discussing the current local and

More information

Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) in the Long Term Care Setting Part 2: HIV Medications

Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) in the Long Term Care Setting Part 2: HIV Medications Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) in the Long Term Care Setting Part 2: HIV Medications Carrie Allen PharmD, CGP, BCPS, BCPP, CCHP Overview - Part 2: HIV

More information

COMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING**, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL

COMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING**, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL COMPREHENSIVE ANTIRETROVIRAL TABLE: NUCLOESIDE/TIDE REVERSE TRANSCRIPTASE INHIBITORS (N(t)RTIs) Abacavir ABC (Ziagen) Didanosine ddi (Videx EC) Emtricitabine FTC (Emtriva) Lamivudine 3TC (Epivir) Stavudine

More information

Antiretroviral Dosing in Renal Impairment

Antiretroviral Dosing in Renal Impairment Protease Inhibitors (PIs) Atazanavir Reyataz hard capsules 300 mg once daily taken with ritonavir 100 mg once daily No dosage adjustment is needed for atazanavir in renal impairment Atazanavir use in haemodialysis

More information

Simplifying HIV Treatment Now and in the Future

Simplifying HIV Treatment Now and in the Future Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line

More information

Sculpting a Better Regimen: The ART of HIV Medications

Sculpting a Better Regimen: The ART of HIV Medications Sculpting a Better Regimen: The ART of HIV Medications Kelly Peddy, PharmD, MPA Clinical Pharmacy Specialist - Ambulatory Care Memorial Hospital of South Bend November 30, 2017 For HealthTrust Members

More information

HIV medications HIV medication and schedule plan

HIV medications HIV medication and schedule plan Living with HIV (human immunodeficiency virus) It may be scary to find out that you re HIV-positive or have AIDS. Coping with this news may be difficult. Although HIV is a serious infection, people with

More information

ANTIRETROVIRAL TREATMENTS (Part 1of

ANTIRETROVIRAL TREATMENTS (Part 1of CCR5 CO-RECEPTOR ANTAGONISTS maraviroc (MVC) Selzentry 25mg, 75mg, FUSION INHIBITORS 20mg/mL ANTIRETROVIRAL TREATMENTS (Part 1of 5) oral soln enfuvirtide (ENF, T-20) Fuzeon 90mg/mL pwd for SC inj after

More information

ART and Prevention: What do we know?

ART and Prevention: What do we know? ART and Prevention: What do we know? Biomedical Issues Trip Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Cornell Medical College New York City ART for Prevention:

More information

Comprehensive Guideline Summary

Comprehensive Guideline Summary Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and

More information

ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals

ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals Antiretroviral Medications: What you need to know Jason J. Schafer, PharmD, MPH, BCPS, AAHIVP Associate Professor, Department of Pharmacy Practice Jefferson College of Pharmacy, Thomas Jefferson University

More information

Third Agent Advantages Disadvantages. Component Tenofovir/emtricitabine (TDF/FTC) 300/200 mg (coformulated with EFV as Atripla) 1 tab once daily

Third Agent Advantages Disadvantages. Component Tenofovir/emtricitabine (TDF/FTC) 300/200 mg (coformulated with EFV as Atripla) 1 tab once daily Table I. Recommended and Alternative Antiretroviral Regimens (DHHS Guidelines, May 1, 2014) Recommended Regimens Nucleoside Analog Reverse Transcriptase Inhibitor (NRTI) Third Agent Advantages Disadvantages

More information

POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV

POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV DISCLOSURE Relevant relationships with commercial entities none Potential for conflicts of interest within this presentation none

More information

JULUCA (dolutegravir sodium-rilpivirine hydrochloride) oral tablet

JULUCA (dolutegravir sodium-rilpivirine hydrochloride) oral tablet JULUCA (dolutegravir sodium-rilpivirine hydrochloride) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific

More information

Approach for the Newly Diagnosed HIV Positive Patient

Approach for the Newly Diagnosed HIV Positive Patient Approach for the Newly Diagnosed HIV Positive Patient Jason E. Farley, PhD, MPH, ANP-BC, FAAN, AACRN Associate Professor & NP, Johns Hopkins University School of Nursing & Medicine Director, AETC Adult-Gerontology

More information

The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines

The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines I. Boucoiran, T. Lee, K. Tulloch, L. Sauve, L. Samson, J. Brophy, M. Boucher and D. Money For and

More information

Overview of HIV WRAIR- GEIS 'Operational Clinical Infectious Disease' Course

Overview of HIV WRAIR- GEIS 'Operational Clinical Infectious Disease' Course Overview of HIV WRAIR- GEIS 'Operational Clinical Infectious Disease' Course UNCLASSIFIED Acknowledgments - Dr. Christina Polyak - Dr. Julie Ake Disclaimer The views expressed in this presentation are

More information

Antiretrovial Crushable/Liquid Formulation Chart

Antiretrovial Crushable/Liquid Formulation Chart Antiretrovial Crushable/Liquid Formulation Chart Eliza Dollard, PharmD; Nafeesa Chin-Beckford, PharmD; Laura Aragon, PharmD Last Updated: 04/2016 Agent How Supplied Crushable Status **Products listed in

More information

WOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION

WOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION WOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION A1. PARTICIPANT ID: ENTER NUMBER HERE - - - ONLY IF ID LABEL IS NOT AVAILABLE A2. VISIT #: A3. VERSION DATE: 1 0 /

More information

Exploring HIV in 2017: What a pharmacist needs to know

Exploring HIV in 2017: What a pharmacist needs to know Exploring HIV in 2017: What a pharmacist needs to know Lifecycle of the HIV virus a. HIV spread through mucous membrane contact, damaged tissue contact, or blood contact with: blood, semen, rectal fluids,

More information

Medscape's Antiretroviral Pocket Guide for the Treatment of HIV Infection

Medscape's Antiretroviral Pocket Guide for the Treatment of HIV Infection Table 3. Characteristics of Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Generic Name (Abbreviation) / Trade Name Abacavir (ABC) / Ziagen Trizivir with ZDV + 3TC Epzicom with 3TC Didanosine (ddi)

More information

The Future of HIV: Advances in Drugs and Research. Shauna Gunaratne December 17, 2018

The Future of HIV: Advances in Drugs and Research. Shauna Gunaratne December 17, 2018 The Future of HIV: Advances in Drugs and Research Shauna Gunaratne December 17, 2018 Overview Epidemiology Science of HIV How HIV treatment and management have changed over the years New medicines and

More information

ABRIDGED ANTIRETROVIRAL TABLE: ADULT DOSING, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL

ABRIDGED ANTIRETROVIRAL TABLE: ADULT DOSING, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL NULOESIDE/TIDE REVERSE TRANSRIPTASE INHIBITORS (N(t)RTIs) Abacavir AB (Ziagen) Emtricitabine FT (Emtriva) Lamivudine 3T (Epivir) Tenofovir disoproxil fumarate TDF (Viread) Zidovudine AZT, ZDV (Retrovir)

More information

HIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop

HIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop HIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop Parya Saberi, PharmD, MAS The Medical Management of HIV/AIDS December 2012 Objectives What are commonly used ARVs and where do they work in

More information

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 03/07/18 SECTION: DRUGS LAST REVIEW DATE: 02/19/19 LAST CRITERIA REVISION DATE: ARCHIVE DATE:

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 03/07/18 SECTION: DRUGS LAST REVIEW DATE: 02/19/19 LAST CRITERIA REVISION DATE: ARCHIVE DATE: FUZEON (enfuvirtide) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs

More information

Daclatasvir (Daklinza ) Drug Interactions with HIV Medications

Daclatasvir (Daklinza ) Drug Interactions with HIV Medications Daclatasvir/Sofosbuvir (Daklinza /Sovaldi TM ) Drug Interactions A Quick Guide for Clinicians April 2017 John J Faragon, PharmD, BCPS, AAHIVP Mechanism of Action and Route of Metabolism for Daclatasvir

More information

Nothing to disclose.

Nothing to disclose. Lisa G. Winston, MD University of California, San Francisco San Francisco General Hospital HIV UPDATE FOR THE PRIMARY CARE PROVIDER Nothing to disclose. 1 Outline Epidemiology Screening / testing for HIV

More information

The ART of Managing Drug-Drug Interactions in Patients with HIV

The ART of Managing Drug-Drug Interactions in Patients with HIV The ART of Managing Drug-Drug Interactions in Patients with HIV Bradley L. Smith, Pharm.D. smith.bradley1@mayo.edu Pharmacy Grand Rounds December 19, 2017 2017 MFMER slide-1 Presentation Objectives Describe

More information

treatment passport 1

treatment passport 1 treatment passport 1 Why keep a treatment history? Keeping a short record of your treatment history can help in many ways. It can help you understand your health and treatment. It can help if your doctor

More information

Overview of HIV. LTC Paige Waterman

Overview of HIV. LTC Paige Waterman Overview of HIV LTC Paige Waterman Outline Background and Epidemiology HIV Virology, Transmission, and Pathogenesis Acute HIV infection HIV Diagnostics Management of Health Care Personnel Exposed to HIV

More information

HIV Treatment Guidelines

HIV Treatment Guidelines HIV Treatment Guidelines Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject What Are Treatment Guidelines? Issued by variety of global and country-based

More information

October 26-28: Training Day 1

October 26-28: Training Day 1 Peer Linkage and Re-Engagement of HIV- Positive Women of Color October 26-28: Training Day 1 Peer Linkage and Re -Engagement of HIV - Positive Women of Color Convening Training Trainers Today: Alicia Downes

More information

0% 0% 0% Parasite. 2. RNA-virus. RNA-virus

0% 0% 0% Parasite. 2. RNA-virus. RNA-virus HIV/AIDS and Treatment Manado, Indonesia 16 november HIV [e] EDUCATION HIV is a 1. DNA-virus 2. RNA-virus 3. Parasite 0% 0% 0% DNA-virus RNA-virus Parasite HIV HIV is a RNA-virus. HIV is an RNA virus which

More information

Epidemiology Testing Clinical Features Management

Epidemiology Testing Clinical Features Management Jason Cronin, MD Epidemiology Testing Clinical Features Management In 1981, 1 the first cases of AIDS were identified among gay men in the US. However, scientists later found evidence that the disease

More information

Criteria for Oral PrEP

Criteria for Oral PrEP Oral PrEP New Drugs Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Safe Criteria for Oral PrEP Penetrates

More information

Pharmacological considerations on the use of ARVs in pregnancy

Pharmacological considerations on the use of ARVs in pregnancy Pharmacological considerations on the use of ARVs in pregnancy 11 th Residential Course on Clinical Pharmacology of Antiretrovirals Torino, 20-22 January 2016 Prof. David Burger, PharmD, PhD david.burger@radboudumc.nl

More information

HIV Clinical Nurse Specialist CCDHB Wellington

HIV Clinical Nurse Specialist CCDHB Wellington RN James Rice-Davies HIV Clinical Nurse Specialist CCDHB Wellington 11:00-11:55 WS #88: Undiagnosed HIV in Your Practice 12:05-13:00 WS #99: Undiagnosed HIV in Your Practice (Repeated) HIV- Undiagnosed

More information

Approach to a Patient Newly Diagnosed with HIV, Including ART Basics Rajesh T. Gandhi, M.D.

Approach to a Patient Newly Diagnosed with HIV, Including ART Basics Rajesh T. Gandhi, M.D. Approach to a Patient Newly Diagnosed with HIV, Including ART Basics Rajesh T. Gandhi, M.D. Disclosures: grant support from Gilead, Roche, EBSCO Objectives Apply current guidelines to initial evaluation

More information

Nobel /03/28. HIV virus and infected CD4+ T cells

Nobel /03/28. HIV virus and infected CD4+ T cells Mechanism of HIV drug resistance. Rodrigo Brindeiro / Amilcar Tanuri Laboratório de Virologia Molecular UFRJ 2 -Asso ciate Research Scientist, Internatio nal Center fo r Aids Care and Treatment Programs-ICAP,

More information

Jonathan Cohn MD Wayne State University July 24,

Jonathan Cohn MD Wayne State University July 24, Jonathan Cohn MD Wayne State University July 24, 2017 www.matecmichigan.org jcohn@med.wayne.edu Current HIV Test Sequence 4 th Generation Ag/Ab Combo > Differentiation Assay Abbott Architect Alere Determine

More information

Principles of Antiretroviral Therapy

Principles of Antiretroviral Therapy Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,

More information

A Fatal Imbalance. Tropical diseases: 18 new drugs (incl. 8 for malaria) 1.3% 21 new drugs for neglected diseases. Tuberculosis: 3 new drugs

A Fatal Imbalance. Tropical diseases: 18 new drugs (incl. 8 for malaria) 1.3% 21 new drugs for neglected diseases. Tuberculosis: 3 new drugs ADDRESSING GAPS IN INNOVATION FOR NEGLECTED PATIENTS: DNDI ANDPEDIATRIC HIV/AIDS Rachel Cohen, Regional Executive Director, DNDi North America Proposals for a Global Innovation System that Responds to

More information

Guidance for Non-HIV-Specialized Providers Caring for Persons with HIV Displaced by Disasters

Guidance for Non-HIV-Specialized Providers Caring for Persons with HIV Displaced by Disasters Guidance for Non-HIV-Specialized Providers Caring for Persons with HIV Displaced by Disasters Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline

More information

Medication Errors Focus on the HIV-Infected Patient

Medication Errors Focus on the HIV-Infected Patient Medication Errors Focus on the HIV-Infected Patient Nimish Patel, Pharm.D., Ph.D., AAHIVP Associate Professor Albany College of Pharmacy & Health Sciences I do not have any conflict of interest in relation

More information

WOMEN'S INTERAGENCY HIV STUDY METABOLIC STUDY: MS01 SPECIMEN COLLECTION FORM

WOMEN'S INTERAGENCY HIV STUDY METABOLIC STUDY: MS01 SPECIMEN COLLECTION FORM WOMEN'S INTERAGENCY HIV STUDY METABOLIC STUDY: MS01 SPECIMEN COLLECTION FORM ID LABEL HERE ---> VERSION DATE 10/01/07 - - - VISIT #: FORM COMPLETED BY: A1. DATE OF BLOOD DRAW: / / M D Y A2. Do you take

More information

Page 1 of 5 ENLGLISH / ESPAÑOL / PORTUGUÉS / FRANÇAIS Share 3 Drug Chart for HIV Treatment CURRENT EDITION ABOUT SENSE BACK ISSUES MSMGF HOME CONTACT US There are a number of antiretroviral (ARV) medications

More information

HIV Infection & AIDS in Low- and Middle-Income Countries

HIV Infection & AIDS in Low- and Middle-Income Countries GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER 25: HIV Infection & AIDS in Low- and Middle-Income Countries Author P. Van de Perre, MD, PhD Chapter Editor Michelle Doll, MD, MPH Topic Outline Key Issues

More information

When to Start ART. Reduction in HIV transmission. ? Reduction in HIV-associated inflammation and associated complications» i.e. CV disease, neuro, etc

When to Start ART. Reduction in HIV transmission. ? Reduction in HIV-associated inflammation and associated complications» i.e. CV disease, neuro, etc When to Start ART Exact CD4 count at which to initiate therapy not known, but evidence points to starting at higher counts Current recommendation: ART for all patients with CD4 count of

More information

Midwestern Underwriting Conference 2016

Midwestern Underwriting Conference 2016 UNDERWRITING HIV: THE FAIRY TALE HAS BECOME REALITY Midwestern Underwriting Conference 2016 Jean-Marc Fix, FSA, MAAA VP, R&D, Optimum Re Insurance Co. AGENDA Where are we with HIV? The risk The ideal case

More information

HIV for the Non-ID Pharmacist

HIV for the Non-ID Pharmacist Disclosures HIV for the Non-ID Pharmacist I have nothing to disclose at this time Carmen Faulkner-Fennell, PharmD, BCPS (AQ-ID) Clinical Pharmacy Specialist--Infectious Diseases Greenville Hospital System

More information

HIV Update. Divya Ahuja, MD Associate Professor of Medicine University of South Carolina School of Medicine

HIV Update. Divya Ahuja, MD Associate Professor of Medicine University of South Carolina School of Medicine HIV Update Divya Ahuja, MD Associate Professor of Medicine University of South Carolina School of Medicine Rates of Diagnoses of HIV Infection among Adults and Adolescents, 2012 United States and 6 Dependent

More information

HIV Update Objectives. Epidemiology. Epidemiology, Transmission and Natural History. Transmission Risk by Exposure. Transmission 9/29/2014

HIV Update Objectives. Epidemiology. Epidemiology, Transmission and Natural History. Transmission Risk by Exposure. Transmission 9/29/2014 Objectives HIV Update 2014 Jay Sizemore, MD, MPH Medical Director Chattanooga CARES Assistant Professor UTCOM Chattanooga 2October 2014 Review HIV epidemiology and screening/testing guidelines Discuss

More information

continuing education for pharmacists

continuing education for pharmacists continuing education for pharmacists HIV/AIDS: Overview and Resources for Pharmacists Mona T. Thompson, R.Ph., PharmD Volume XXXIII, No. 9 Dr. Mona T. Thompson has no relevant financial relationships to

More information

SOUTH FLORIDA SE AIDS EDUCATION & TRAINING CENTER. HIV and Oral Health in the Era of Antiretroviral Therapy

SOUTH FLORIDA SE AIDS EDUCATION & TRAINING CENTER. HIV and Oral Health in the Era of Antiretroviral Therapy SOUTH FLORIDA SE AIDS EDUCATION & TRAINING CENTER HIV and Oral Health in the Era of Antiretroviral Therapy SOUTH FLORIDA SE AIDS EDUCATION & TRAINING CENTER Mark Schweizer, DDS MPH Director of Development

More information

1/13/16. Updated April 2015

1/13/16.   Updated April 2015 Bernadette Jakeman, PharmD, PhC, BCPS, AAHIVP Assistant Professor UNM College of Pharmacy bjakeman@salud.unm.edu Pharmacist objectives: 1. Summarize key updates to the DHHS treatment guidelines. 2. Identify

More information

HIV Treatment: New and Veteran Drugs Classes

HIV Treatment: New and Veteran Drugs Classes HIV Treatment: New and Veteran Drugs Classes Jonathan M Schapiro, MD National Hemophilia Center Stanford University School of Medicine Rome, March 2013 Overview Many excellent antiretroviral agents are

More information

Treatment of respiratory virus infection Influenza A & B Respiratory Syncytial Virus (RSV)

Treatment of respiratory virus infection Influenza A & B Respiratory Syncytial Virus (RSV) Treatment of respiratory virus infection Influenza A & B Respiratory Syncytial Virus (RSV) Amantadine and Rimantadine Use is limited to Influenza A infection. Very effective in preventing infection if

More information

Didactic Series. Switching Regimens in the Setting of Virologic Suppression

Didactic Series. Switching Regimens in the Setting of Virologic Suppression Didactic Series Switching Regimens in the Setting of Virologic Suppression Craig Ballard, PharmD, AAHIVP UC San Diego Health Owen Clinic June 14 th, 2018 1 Learning Objectives 1) Describe DHHS guidelines

More information

HIV Diagnosis and Management 2015 Update. Faria Farhat, MD MedStar Washington Hospital Center

HIV Diagnosis and Management 2015 Update. Faria Farhat, MD MedStar Washington Hospital Center HIV Diagnosis and Management 2015 Update Faria Farhat, MD MedStar Washington Hospital Center Objectives Describe the epidemiology and pathogenesis of HIV infection Highlight HIV diagnosis algorithm and

More information

Important Safety Information About TRUVADA for a Pre-exposure Prophylaxis (PrEP) Indication. For Healthcare Providers

Important Safety Information About TRUVADA for a Pre-exposure Prophylaxis (PrEP) Indication. For Healthcare Providers Important Safety Information About TRUVADA for a Pre-exposure Prophylaxis (PrEP) Indication For Healthcare Providers About TRUVADA for a PrEP Indication INDICATION AND PRESCRIBING CONSIDERATIONS TRUVADA,

More information

Addressing Pediatric Needs of the Most Neglected: next steps

Addressing Pediatric Needs of the Most Neglected: next steps Addressing Pediatric Needs of the Most Neglected: next steps An updated overview of DNDi Pediatric Focus Nathalie Strub Wourgaft (Medical Director) Janice Lee (HIV Pediatric Clinical Manager) A Fatal Imbalance

More information

Pediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV. Ernesto Parra, M.D., M.P.H.

Pediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV. Ernesto Parra, M.D., M.P.H. Pediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV Ernesto Parra, M.D., M.P.H. Adjunct Associate Professor UTHSCSA Department of Pediatrics and Family and Community

More information

HIV/AIDS Prenatal Care for HIV+ Mothers. 1. Algorithm for Prenatal Screening & Care (Antepartum)

HIV/AIDS Prenatal Care for HIV+ Mothers. 1. Algorithm for Prenatal Screening & Care (Antepartum) 1. Algorithm for Prenatal Screening & Care (Antepartum) 2. Algorithm for Prenatal HIV Screening and Care (Mother refuses screening) 3. Algorithm for Intrapartum Care 4. Prenatal Care for HIV+ Mothers a.

More information

0.14 ( 0.053%) UNAIDS 10% (94) ( ) (73-94/6 ) 8,920

0.14 ( 0.053%) UNAIDS 10% (94) ( ) (73-94/6 ) 8,920 0.14 UNAIDS 0.053% 2 250 60 10% 94 73 20 73-94/6 8,920 12 43 Public Health Service Task Force Recommendations 5-10% for Use of Antiretroviral Drugs in 10-20% Pregnant HIV-1-Infected Women for Maternal

More information

A Changing Landscape: New and Pipeline HIV Therapies

A Changing Landscape: New and Pipeline HIV Therapies A Changing Landscape: New and Pipeline HIV Therapies Sarah Turley, PharmD, BCPS PGY2 Internal Medicine Pharmacy Resident Virginia Commonwealth University Health System Financial Disclosure I have no relevant

More information

HIV Pathology and ART Basics A Review for Non-Prescribing Clinical Staff

HIV Pathology and ART Basics A Review for Non-Prescribing Clinical Staff HIV Pathology and ART Basics A Review for Non-Prescribing Clinical Staff Dr. Brent J. Pimentel, MD/MPH Texas Program Manager South Central AETC Parkland Health & Hospital System Dallas, TX 1 Objectives

More information

2015 OPSC Annual Convention. syllabus. February 4-8, 2015 Hyatt Regency Mission Bay San Diego, California

2015 OPSC Annual Convention. syllabus. February 4-8, 2015 Hyatt Regency Mission Bay San Diego, California 2015 OPSC Annual Convention syllabus February 4-8, 2015 Hyatt Regency Mission Bay San Diego, California SUNDAY, FEBRUARY 8, 2015: 10:00am - 11:00am Primary Care of the HIV Patient Presented by Jim Lee,

More information

The ART of Antiretroviral Therapy in Critically-ill Patients with HIV

The ART of Antiretroviral Therapy in Critically-ill Patients with HIV The ART of Antiretroviral Therapy in Critically-ill Patients with HIV Tyler Finocchio, PharmD, BCPS PGY2 Critical Care Pharmacy Resident Avera McKennan Hospital & University Health Center February 10 th,

More information

Starting Immediate Treatment for HIV-1

Starting Immediate Treatment for HIV-1 Starting Immediate Treatment for HIV-1 Ronald P. Hattis, MD, MPH Email: ronhattis@foundation.beyondaids.org Associate Prof. of Preventive Medicine, Loma Linda University Secretary, Beyond AIDS Foundation

More information

The ABCs of ART: Designing Initial Antiretroviral Regimens for Beginners

The ABCs of ART: Designing Initial Antiretroviral Regimens for Beginners The ABCs of ART: Designing Initial Antiretroviral Regimens for Beginners Elizabeth Sherman, PharmD, AAHIVP Faculty South Florida, Southeast AETC Clinical Pharmacist, Memorial Healthcare System Assistant

More information

Human Immunodeficiency Virus (HIV)

Human Immunodeficiency Virus (HIV) HIV INFECTION! Human Immunodeficiency Virus (HIV) Infects human cells and causes gradual loss of immune system function, and these immune alterations predispose to the opportunistic infections, neoplasms,

More information

Fundamentals of Antiretroviral Therapy

Fundamentals of Antiretroviral Therapy Fundamentals of Antiretroviral Therapy Southeast AIDS Education & Training Center HIV Clinical Overview 12 May 2016 Todd Hulgan, MD, MPH Department of Medicine, Division of Infectious Diseases Vanderbilt

More information

This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts

This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts 1 2 This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts decreased. This period of acute infection or serocnversion

More information

Susan L. Koletar, MD

Susan L. Koletar, MD HIV/AIDS Susan L. Koletar, MD Division Director, Infectious Diseases Professor of Internal Medicine Department of Internal Medicine The Ohio State University Wexner Medical Center HIV through the Decades

More information

Structured Treatment Interruption in HIV Positive Patients. Leah Jackson, BScPhm Pharmacy Resident HIV Rotation January 23, 2007

Structured Treatment Interruption in HIV Positive Patients. Leah Jackson, BScPhm Pharmacy Resident HIV Rotation January 23, 2007 Structured Treatment Interruption in HIV Positive Patients Leah Jackson, BScPhm Pharmacy Resident HIV Rotation January 23, 2007 Objectives To become re-acquainted with the basics of HAART for HIV infection

More information

Overview of HIV. Christina Polyak, MD, MPH. Research Physician. U.S. Military HIV Research Program, Walter Reed Army Institute of Research

Overview of HIV. Christina Polyak, MD, MPH. Research Physician. U.S. Military HIV Research Program, Walter Reed Army Institute of Research Overview of HIV Christina Polyak, MD, MPH Research Physician U.S. Military HIV Research Program, Walter Reed Army Institute of Research The views expressed are those of the authors and should not be construed

More information

NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS IN HIV PREVENTION. Jason E. Vercher, PA-C, AAHIVM

NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS IN HIV PREVENTION. Jason E. Vercher, PA-C, AAHIVM NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS IN HIV PREVENTION Jason E. Vercher, PA-C, AAHIVM Disclosures No disclosures to report Learning Objectives q Identify Individuals who would benefit from non-occupational

More information

TORONTO GENERAL HOSPITAL HIV AMBULATORY CARE ROTATION

TORONTO GENERAL HOSPITAL HIV AMBULATORY CARE ROTATION TGH - ambulatory rotation page 1 of 5 TORONTO GENERAL HOSPITAL HIV AMBULATORY CARE ROTATION SITE: Immunodeficiency Clinic, Toronto General Hospital, University Health Network Location: 13 th floor, Norman

More information

Objectives. HIV Treatment in Recently In 1996 the introduction of protease inhibitors decreasing the death rate of those infected by 50%.

Objectives. HIV Treatment in Recently In 1996 the introduction of protease inhibitors decreasing the death rate of those infected by 50%. Objectives Identify modes HIV transmission and methods of prevention. HIV Treatment in 2010 Lisa D. Inge, Pharm.D., BCPS, AAHIVE Assistant Director, Jacksonville Campus Clinical Assistant Professor University

More information

I. HIV Epidemiology. HIV Infection A Primer. Objectives. Disclosures 7/18/2014

I. HIV Epidemiology. HIV Infection A Primer. Objectives. Disclosures 7/18/2014 Objectives HIV Infection A Primer Discuss the worldwide and domestic epidemiology of HIV infection Review HIV Biology Review HIV Transmission and Prevention Review HIV diagnosis Describe the approaches

More information

STRIBILD (aka. The Quad Pill)

STRIBILD (aka. The Quad Pill) NORTHWEST AIDS EDUCATION AND TRAINING CENTER STRIBILD (aka. The Quad Pill) Brian R. Wood, MD Medical Director, NW AETC ECHO Assistant Professor of Medicine, University of Washington Presentation prepared

More information

HIV Treatment Evolution. Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare

HIV Treatment Evolution. Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare HIV Treatment Evolution Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare Overview of the Evolution of Antiretroviral Therapy Early Treatment 1987

More information

HIV THERAPY STRATEGIES FOR THIRD LINE. issues to consider when faced with few drug options

HIV THERAPY STRATEGIES FOR THIRD LINE. issues to consider when faced with few drug options STRATEGIES FOR THIRD LINE HIV THERAPY issues to consider when faced with few drug options A PUBLICATION FROM Information, Inspiration and Advocacy for People Living With HIV/AIDS MAY 2008 Most people living

More information

Blood-Borne Pathogens and Post-Exposure Prophylaxis

Blood-Borne Pathogens and Post-Exposure Prophylaxis Blood-Borne Pathogens and Post-Exposure Prophylaxis Christopher Behrens MD Northwest Association of Occupational and Environmental Medicine October 2017 with thanks to Shireesha Dhanireddy MD Disclosures

More information

CLINICAL PEARLS OF NEW HIV MEDICATIONS PHARMACIST OBJECTIVES TECHNICIAN OBJECTIVES. At the end of this presentation pharmacists will be able to:

CLINICAL PEARLS OF NEW HIV MEDICATIONS PHARMACIST OBJECTIVES TECHNICIAN OBJECTIVES. At the end of this presentation pharmacists will be able to: CLINICAL PEARLS OF NEW HIV MEDICATIONS Cindy Lou Zoellner, PharmD, BCPS Added Qualifications in Infectious Diseases Senior Clinical Pharmacy Specialist in HIV Parkland Health & Hospital System Volunteer

More information

HIV/AIDS HIV/AIDS: Outline. Morbidity and Mortality Weekly Report (MMWR)

HIV/AIDS HIV/AIDS: Outline. Morbidity and Mortality Weekly Report (MMWR) HIV/AIDS: Outline HIV/AIDS 2013 Roy M. Gulick, MD, MPH Professor of Medicine Chief, Division of Infectious Diseases Weill Medical College of Cornell University New York City January 31, 2013 Epidemiology

More information

HIV THERAPY STRATEGIES FOR FIRST LINE. issues to think about when going on therapy for the first time

HIV THERAPY STRATEGIES FOR FIRST LINE. issues to think about when going on therapy for the first time STRATEGIES FOR FIRST LINE HIV THERAPY issues to think about when going on therapy for the first time A PUBLICATION FROM Information, Inspiration and Advocacy for People Living With HIV/AIDS MAY 2008 Deciding

More information

Overview of HIV WRAIR- GEIS 'Operational Clinical Infectious Disease' Course

Overview of HIV WRAIR- GEIS 'Operational Clinical Infectious Disease' Course Overview of HIV WRAIR- GEIS 'Operational Clinical Infectious Disease' Course The opinions or assertions contained herein are the private views of the author, and are not to be construed as official, or

More information

What's new in the WHO ART guidelines How did markets react?

What's new in the WHO ART guidelines How did markets react? WHO 2013 ARV Guidelines What's new in the WHO ART guidelines How did markets react? Dr. J. Perriëns Coordinator, HIV Technology and Commodities HIV department, WHO, Geneva When to start in adults Starting

More information

Fluconazole dimenhydrinate, diphenhydramine. Raltegravir or dolutegravir with antacids

Fluconazole dimenhydrinate, diphenhydramine. Raltegravir or dolutegravir with antacids Supportive therapy Summary of interactions Table 1. Summary of potential interactions between antiretroviral agents and supportive therapy Interactions with enzyme inhibitors (protease inhibitors and elvitegravir/cobicistat)

More information

2016 Perinatal Treatment Guidelines Update

2016 Perinatal Treatment Guidelines Update Mountain West AIDS Education and Training Center 2016 Perinatal Treatment Guidelines Update Shireesha Dhanireddy, MD Associate Professor of Medicine, University of Washington 2 November 2016 This presentation

More information

First line ART Rilpirivine A New NNRTI. Chris Jack Physician, Durdoc Centre ethekwini

First line ART Rilpirivine A New NNRTI. Chris Jack Physician, Durdoc Centre ethekwini First line ART Rilpirivine A New NNRTI Chris Jack Physician, Durdoc Centre ethekwini Overview: Rilpirivine an option for ARV Naïve patients History Current guidelines Efficacy and Safety Tolerability /

More information